The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial by Braido, F et al.
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a  b  s  t  r  a  c  t
Studies  in  the  1970s  and  1980s reported  that bacterial  lysates  (BL)  had  a prophylactic  effect  on  recurrent
respiratory  tract  infections  (RRTI).  However,  controlled  clinical  study  procedures  have  evolved  substan-
tially  since  then.  We  performed  a trial using  updated  methods  to  evaluate  the  efficacy  of  Lantigen  B®, a
chemical  BL.  This  double  blind,  placebo  controlled,  multi-center  clinical  trial  had  the  primary  objective
of  assessing  the  capacity  of  Lantigen  B to significantly  reduce  the  total  number  of infectious  episodes  inllergy
rophylactic treatment
mmune-stimulant drugs
patients  with  RRTI.  Secondary  aims  were  the  RRTI duration,  the  frequency  and  the  severity  of  the  acute
episodes,  the  use  of  drugs  and the  number  of  missed  workdays.  In  the subgroup  of  allergic  patients  with
RRTI,  the number  of allergic  episodes  (AE)  and  the use  of  anti-allergic  drugs  were  also  evaluated.  One
hundred  and  sixty  patients,  79  allocated  to the  treated  group  (TG)  and 81  to the  placebo  group  (PG),  were
enrolled;  30  were  lost  during  the  study  and  120  (79 females  and  38  males)  were  evaluated.  The  PG had
1.43  episodes  in  the 8-months  of  follow-up  while  the  TG  had  0.86  episodes  (p  = 0.036).  A  similar  result  was
observed  in  the  allergic  patients  (1.80  and  0.86  episodes  for the  PG  and  the  TG,  respectively,  p =  0.047).
∗ Corresponding author. Tel.: +39 346 5168826.
E-mail address: giovannimelioli@gmail.com (G. Melioli).
ttp://dx.doi.org/10.1016/j.imlet.2014.10.026
165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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The  use  of antibiotics  was  reduced  (mean  1.24 and  2.83  days  of treatment  for the TG  and  the  PG).  Logistic
regression  analysis  indicated  that  the  estimated  risk  of needing  antibiotics  and  NSAIDs  was  reduced  by
52.1  and  30.6%,  respectively.  With  regard  to the number  of  AE,  no  significant  difference  was  observed
between  the  two groups,  but bronchodilators,  antihistamines  and  local  corticosteroids  were  reduced  by
25.7%,  56.2%  and  41.6%,  respectively,  in the  TG.  Lantigen  B significantly  reduced  the number  of  infectious
episodes  in  patients  with  RRTI.  This  finding  suggests  a first  line  use  of this  drug for  the  prophylaxis  of
infectious  episodes  in these  patients.
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. Introduction
Recurrent respiratory tract infections (RRTI) are less frequent in
dults than in the children, but the frequency of patients affected
emains significant [1]. The therapy is based on anti-inflammatory
rugs and antibiotics, and only rarely is infection prophylaxis pro-
ided. Bacterial lysates (BL) are a family of “biological” drugs that
ere introduced in therapy many decades ago, but only in the
ast 10 years has their mechanism of action has been elucidated.
ince the first in vivo studies, it was hypothesized that the clinical
ffects observed were related to the capacity of BL to elicit a spe-
ific immune-response against bacterial antigens. Along this line,
ince the mid  1970s, specific IgA directed against bacterial antigens
ave been observed in the salivary fluid of treated patients [1–4]
ollowing the oral administration of bacterial lysates. During the
990s, the description of the toll-like receptor (TLR) family and its
unctions [5] within the larger context of the pattern recognition
eceptor (PRR) system explained how the innate immune system
as alerted by the presence of different stimuli, mainly represented
y bacterial derived structures. In that same period, the central role
f dendritic cells (DC) in the generation of an efficient immune-
esponse was described [6]. Starting from these lines of evidence,
ifferent bacterial lysates were shown to be able to induce signif-
cant activation and maturation of DC in vitro [7,8]. More recently,
sing a specific member of the bacterial lysate family (the Poly-
alent Mechanical Bacterial Lysate – PMBL), other relevant effects
ere observed on B cells, T cells and NK cells [9,10] and these
ffects were also correlated with the clinical results [11,12]. Bacte-
ial lysates are obtained by physical or chemical lysis. The former
re in general composed of fragments of bacterial bodies. The latter
ay  be constituted by either only low molecular weight proteins
r a mixture of bacterial bodies and soluble proteins. Lantigen B
elongs to the latter family, being a suspension of bacterial anti-
ens obtained from Streptococcus pneumoniae type 3, Streptococcus
yogenes Group A, Branhamella catarrhalis,  Staphylococcus aureus,
emophilus influenzae type b and Klebsiella pneumoniae. The in vivo
ffects of Lantigen B were first described in the mid  1970s [11–13].
ince that time, few studies have been performed on this specific
rug. Although the first studies were considered obsolete from a
rocedural point of view [14–16], the drug remained in the phar-
acological armamentarium of both general practitioners and spe-
ialists. In this context, other studies even if not totally in line with
odern clinical trial practice have been published [17–19], further
emonstrating the clinical efficacy of Lantigen B. In particular, the
ain effect observed was the reduction of infections during the
bservation period. Indeed, by analyzing all the abovementioned
tudies, it can be calculated that a mean of 1.73 episodes/year were
bserved in treated patients vs. 2.63/year in the placebo group,
orresponding to a reduction of 34% of the number of infectious
pisodes. In addition, in the same studies, the reduction of cough,
f lost days and antibiotics use was also observed. Of note, only one
on-positive study on the common cold [20] was published, while
ll the others demonstrated the efficacy of the treatment.
In this study, using modern and effective clinical practice
ools, we re-evaluated the efficacy of Lantigen B in a doublehed  by  Elsevier  B.V. This  is  an  open  access  article  under the  CC  BY  license
(http://creativecommons.org/licenses/by/3.0/).
blind randomized placebo-controlled clinical trial in inducing
a significant reduction in the number of infectious episodes
in an unselected (real life-like) population of patients with
RRTI. This type of study is needed not only to verify previous
results using an up-dated methodology but also for the avail-
ability of drugs (such as third generation anti-histamine, local
corticosteroids and modern bronchodilators) that have recently
demonstrated a deep impact on the management of allergic
patients who represent a significant fraction of patients with
RRTI.
2. Material and methods
2.1. Definition of acute infectious episodes
Acute episodes of the upper respiratory airways were identi-
fied by the continuous presence of rhinorrhea (both sero-mucous
and purulent), pharyngitis, and couch, lasting at least 48 h, with or
without fever. Acute episodes of the lower respiratory airways were
defined as the continuous presence of stridor, wheeze, crackles
and rhonchi, an indrawing respiratory frequency > 50 cycles/min, or
cyanosis lasting at least 48 h, with or without fever. Acute episodes
of otitis were defined as the continuous presence of pain, erythema
and a reduction in or loss of tympanic membrane mobility. Finally,
an acute infectious episode was  defined as new if at least 72 h had
passed with a complete absence of symptoms from the resolution
of the previous episode. The identification of an infectious event
was based on patient’s report (fever or cough or dyspnea or use
of drugs) as well as on doctor’s report (visits and therapeutic indi-
cations). The protocol provided that when an infectious episode
occurs, the patient might contact to the primary care physician or
the study center that enrolled her/him. In both cases, the diagnosis
and the therapy were reported in the patient’s diary and in the Case
Report Form.
2.2. Study design
This was  a national multi-center longitudinal, prospective ran-
domized double blind versus placebo controlled clinical phase
IV study, conducted on two  parallel groups for an observation
period of 8 months. The protocol EudraCT code was 2011-00-
3229-76. The primary goal was  the evaluation of the efficacy of
the Lantigen B treatment on the number of infectious episodes
(IE) in the group of treated patients. Secondary goals were (a)
the total number of days with IE (in a 6 month follow-up); (b)
the frequency and severity of episodes of allergy (AE), in partic-
ular asthma and rhino-conjunctivitis; (c) the disease free period
evaluated as the time of occurrence of an IE after the end of one
of the treatment cycles; (d) any other drug consumption in the
8 month period, including anti-infectious, anti-inflammatory and
anti-allergic drugs; (e) the enumeration of days of absence from
the community (school, work); (f) the safety and tolerability of the
treatment.
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.3. Study approval
The study was conducted in accordance with good clinical
ractice was also approved by the Ethical Committee (EC) of the
niversity of Genova and the AOU San Martino, reference of the
nstitution of the Principal Investigator. The other 10 ECs of the
emaining 11 centers also approved the protocol.
.4. Study timing
The study recruitment started in September 2012 and finished
t the end of December 2012. The follow-up finished and the study
as closed in September 2013. The clinical and statistical data were
vailable from December 2013.
.5. Patient selection
The study was carried out at 12 different centers, represen-
ative of the different Italian climates. This study enrolled men
nd woman between the ages of 18 and 65 years. Inclusion
riteria were: (a) patients complaining two or more infections
f the upper respiratory in the year preceding this study, pos-
ibly associated with respiratory allergy, (b) the absence of any
ype of malformation or other significant diseases (i.e., cancer,
mmunological disorders), and (c) the capacity to understand the
tudy and collaborate with the investigators. Exclusion criteria
ere: (a) recurrent respiratory infections in the last 7 days before
nrollment; (b) acute diseases (either infectious or not infectious)
equiring hospitalization; (c) gastro-esophageal reflux; (d) cys-
ic fibrosis, 1-antitrypsin defects or ciliar diskynesis; (e) any
hronic systemic disease; (f) body mass < 3th percentile for age;
g) autoimmune diseases; (h) any drugs such as immunoglobulins,
mmunostimulants, antineoplastic drugs, cytokines, interferons,
nterleukins, immunosuppressors, or systemic corticosteroids; (i)
nown allergy or intolerance to the study product or its excipients;
k) patients who could not be contacted by telephone during the
tudy; (l) patients recruited into any other clinical study in the last
onth before the enrollment or during the study.
.6. Randomization protocol
The randomized list was based on the “RANUNI” random num-
er generator of the SAS software (SAS Institute, Cary, NC, USA).
he type was a 1:1 randomization of two groups.
.7. Treatment
The treated group received Lantigen B (Bruschettini Srl,) in oral
rops. Lantigen B is a suspension of bacterial antigens obtained
rom S. pneumoniae type 3, S. pyogenes group A, B. catarrhalis,  S.
ureus, H. influenzae type b and K. pneumoniae in distilled water,
H 7.30, containing undetectable doses of chlorhexidine diacetate
able 1
tudy plan.
First cycle
Month 0 1 2 
Week  0 1 2 3 4 5 6 7 8 
Treatment * * * * * * 
Visit  X 
Second cycle
Month 5 6 
Week  17 18 19 20 21 22 23 24
Treatment * * * * * * 
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(0.02 mg/mL). The placebo control had the same characteristics
(namely, aspect, pH, and chlorhexidine), but the bacterial anti-
gens were not present in the bottles. A 4-week cycle of treatment
represented by a total of 30 drops in two  different daily admin-
istrations (15 + 15), morning and evening, fasting, was  scheduled,
followed by an interval of 2 weeks and another 4 weeks of treat-
ment. After a 6-week observation period, two additional 4-week
treatments were scheduled, with an interval of 2 weeks. At the end
of the second treatment cycle, the patients were followed-up for
another 6 weeks. Table 1 shows the treatment schedule. During
the period of the study, immune-stimulant drugs, cytokines, inter-
ferons, immune-suppressors and anti-neoplastic drugs were not
allowed. Systemic steroids, if used continuously for more than 2
weeks, were also not allowed. The use of forbidden drugs caused the
exclusion of patients from the study. Any other drug was allowed
and recorded in the patient’s personal diary.
2.8. Visits
Three visits were scheduled during the treatment: a first visit,
which included the enrollment, a second visit before the beginning
of the second 4 + 4 week cycle and a third visit at the end of the
second follow-up period. During the first visit, the patients were
evaluated to define whether the inclusion and the exclusion criteria
were met. In positive cases, the patients were asked to be enrolled
in the clinical trial. If enrolled, in the same visit, the patients under-
went a physical examination for the evaluation of vital signs and
they were further evaluated for their life style, clinical history
and smoking habits. The enrolled patients signed the informed
consent and were included in the randomization procedure by
receiving the study drug. All the patients were then trained in the
use of the drop dispenser and were instructed by the investigator
regarding when and how to take the daily treatment, according
to the provided schedule. Finally, the patients were exhaustively
instructed to compile a daily diary and were asked to record any
relevant events that occurred. Thus, in the presence of a decline in a
patient’s conditions, the symptoms were recorded and the intensity
was evaluated using a 4-point scale from 0 (absence) to 3 (pres-
ence of severe symptoms). The administered drugs, medical visits
and possible hospitalization were also recorded in the diary. The
patients were also asked to carefully record the use of the study
drug according to the provided schedule. They were also required
to return the bottles and the containing boxes to the investigator at
their next visit. During the second visit, the investigators recorded
any adverse reactions, hospitalization periods, modifications of life
style, work or school habits and drug use (in particular antibiotics,
anti-inflammatory drugs etc.). At the same visit, the first phase diary
was retired and both infectious and allergic episodes were recorded
in the Case Report Form (CRF). The remaining drug was  also retired
and the drug for the second cycle was given together with the sec-
ond part of the diary. The third and final visit (at the end of the
second period of observation) was used to record the same param-
3 4
9 10 11 12 13 14 15 16
* *
X
7 8 End
 25 26 27 28 29 30 31 32
* *
X
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Table 2
Clinical characteristics of the patients, number of patients with a given diseases and
number of episodes of disease in the period of the study (2012–2013).
Patients with disease Number of disease
episodes
Placebo Lantigen B Placebo Lantigen B
Otitis 2 1 2 1
Tonsillitis 5 2 7 2
Sinusitis 9 3 18 6
Pharyngotonsillitis 17 11 23 15
Rhinopharyngitis 20 18 32 21
Bronchitis 15 8 23 1288 F. Braido et al. / Immunolo
ters as the second visit and to retire the remaining drug and the
iary.
.9. Patient consent withdrawal
Patients were allowed to withdraw from the treatment for any
eason. When possible, the adverse reactions and the use of drugs
ere recorded for the retired patients and the personal diary was
etired. Any relevant information was recorded in the CRF.
.10. Patient compliance control
The compliance to the treatment was evaluated by compar-
ng the registered doses and the amount of remaining drug in the
ottles.
.11. Safety assessments
The patients and the investigators were asked to monitor
he possible occurrence of adverse reactions (ARs). These were
lassified as certain, likely, possible, unlikely, unrelated and not
valuable, according to the definition of the protocol. ARs were also
lassified as slight (if not interfering with daily activities), interme-
iate (if the AR interfered with the day activities) and severe (if the
R inhibited daily activities).
.12. Exclusion of patients from the study
Patients were excluded from the study in the presence of a
evere AR incompatible with the continuation of participation in
he study.
.13. Viro-epidemiological survey of the study period
The frequency of viral infections in the general population dur-
ng the period of the study and the previous year was  evaluated. The
esults of molecular biology-based research on influenza viruses,
ara-influenza viruses, bocaviruses, coronaviruses. Rhinoviruses,
nteroviruses, adenoviruses and Respiratory Syncytial virus were
ecorded. The frequency of viral infections was based on the per-
entage of positive samples as described [10]. Thus, an increase in
he percentages of positive samples was considered representative
f an increased circulation of pathogens in a given period.
.14. Statistical analysis
For the sample size calculation, a total of 190 patients (85
atients per group) were required to be recruited, by considering
n expected drop out of 15% of the patients enrolled with the inten-
ion to treat (ITT). Thus, a total of 160 patients were expected to be
valuable. The primary efficacy analysis was based on the ITT. The
fficacy of the treatment on the two groups was evaluated by an
nalysis of covariance (ANCOVA). For this analysis, the total num-
er of infective episodes was the dependent variable, the treatment
roup was the factor and the number of previous year infective
pisodes was the covariate. In the ANCOVA model, the adjustment
or baseline covariates was performed. The subgroup analyses were
erformed in compliance with the rules suggested in the European
edicine Agency Guideline on the investigation of subgroups in
onfirmatory clinical trials. Binary variables measuring the effects
f treatment on the secondary objectives were analyzed by a 2est. Finally, a logistic regression (multivariate) analysis was  used
o evaluate the probability of using drugs: antibiotics and NSAID,
or the whole population and local corticosteroids, antihistamine
rugs and bronchodilators for the subset of allergic patients. AllPneumonia 0 1 0 1
Total 68 44 105 58
these statistics were carried out by using SPSS on data extracted
from the CRFs.
3. Results
3.1. Study population
A total of 160 patients (79 in the treated group and 81 in the
placebo group) were enrolled. The age of the placebo group was
42.4 ± 15.14 (mean ± standard deviation) and the age of the treated
group was  42.4 ± 13.94 years. One hundred and seventeen patients
(58 in the treated and 59 in the placebo group) completed the study
(Fig. 1). The drop out was observed both in the Lantigen B group
(17 patients) and in the placebo group (23 patients). Some patients
were lost for inadequate compliance or violation of the protocol
(seven patients), three for adverse reactions, five were lost in the
follow-up and 23 (corresponding to the 57.5%) for consent with-
drawal. Finally, two were lost for other reasons. In patients who
completed the study, the genders were equilibrated between the
placebo (20 males and 38 females) and in the treated group (18 and
41, respectively) (2 = 0.21, p = 0.65). Table 2, in the lanes related to
the reference period (2011–2012) shows the clinical characteristics
of these patients, in line with the eligibility criteria.
3.2. Post-hoc power
The number of patients recruited and the number of drop-outs
could have impacted the power of the study results. However,
because the differences between the placebo and treatment were
significant and the efficacy of the treatment was higher than could
have been expected on the basis of the published literature, the
post-hoc power of the study was confirmed. Indeed, a sample size
of 58 in each group had an 84% power to detect a probability of 0.34
that an observation in the Lantigen B group was less than an obser-
vation in the placebo group (Wilcoxon Rank-sum test with a 0.05
two sided significance level). Of note, a power of 80% is considered
acceptable by the scientific community for clinical studies. Thus, the
original design of this study had a power suitable to achieve com-
plete statistical significance even in the presence of a conspicuous
drop-out of the enrolled patients.
3.3. The primary objective
The primary objective of the study was the reduction of the
number of IE during an 8 months follow-up period. In the whole
group of enrolled patients, the mean frequency of IE in the year
preceding the study was 3.66/year (C.I. 3.38–3.93). The frequency
was 3.34/year for males and slightly higher, 3.81/year for females,
corresponding to a mean 2.56 IE in 8 months (2.5 and 2.9 in 8
months, respectively). The distribution of IE between the placebo
F. Braido et al. / Immunology Letters 162 (2014) 185–193 189
sort 2010 flowchart.
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Fig. 2. Percentages of IE episodes (Y axis) distributed per number of episodes (from
0  to 9) (X axis) during the study period. Panel (A) Pre-study results. Panel (B) Placebo
group results. Panel (C) Lantigen B group results. The arrows indicate the two zero
values representing the eligibility criteria of the study (i.e., eligible patients had
>2  episodes of respiratory airways infections in the previous year). Both 0 andFig. 1. The Con
nd treated groups was 3.78 and 3.54, respectively. During the
eriod of the study, the placebo group (58 patients) experienced
 mean of 1.43 (C.I. 1.01–1.86) episodes in the 8 month study
eriod, while 0.86 (C.I. 0.54–1.19) episodes were recorded in the
9 patients of the active group (t-test = 2.129, p = 0.036). To further
upport this difference, a non-parametric analysis of the number
f infectious episodes showed a median value of 0 in the treated
roup and 1 in the placebo group. To better define this result,
he difference in episodes in the single patients was  also evalu-
ted. For this, the frequency of the patients with 0, 1, 2 etc. IE
as analyzed. Fig. 2 shows the frequency of IE in the pre-study
opulation, in the Lantigen B treated group and in the placebo
roup. The placebo group had more IE/patients (2 = 14.7, p = 0.023)
hen compared with the active group. With regard to the diseases
uffered by the patients, the frequency was 16% for pharyngoton-
illitis (PT), 36% for rhinopharyngitis (RP) and 22% for bronchitis
B); the remaining 26% were otitis, tonsillitis, sinusitis and, rarely,
neumonia. After the treatment with Lantigen B, the total num-
er of infections was significantly reduced, as stated before, but
he relative frequency of different clinical pictures remained vir-
ually unmodified (25% for PT, 41% for RP, 18% for B), while others
ere slightly reduced to 16% (Table 2). A subgroup analysis of those
atients suffering from respiratory allergy (22 in the placebo and
2 in the treated group, according to the evidence collected during
he eligibility visit) was  also performed. Of these patients, only 24
ad allergic episodes during the study period: 9 had oculorhinits,
1 had asthma and 4 had both. Of note, the frequency of IE in those
atients with allergy was slightly higher (3.80 IE/8 months) that in
he non-allergic patients (3.58 IE/8 months) even if not significant
t = −0.81, p = 0.42). Like the original population, non-significantly
ifferent effects were observed when the gender (12 males and 321  episodes were absent in the “pre-study” period because of the strict eligibility
criteria. During the treatment, these two groups appeared.
females) of the allergic patients was evaluated. Similarly, no sig-
nificant effects on the treatment results were observed when the
smoking habits and the different clinical centers were evaluated
(ANCOVA, F = 1.473, p = 0.227 and F = 1.817, p = 0.087, respectively).
190 F. Braido et al. / Immunology Letters 162 (2014) 185–193
Table 3a
Adverse reaction in the active group.
Patient Adverse reaction Seriousness Intensity Action Relationships with the drug
2 Headache Not serious Light None None
2  Dry and burning mouth Not serious Intermediate None Possible
2  Dry and burning mouth Not serious Intermediate None Possible
31  Trauma, left ankle Not serious Light None None
32  Nasopharynx biopsy Serious Light None None
35  Persistent cough Not serious Light None None
57  Hypothyroidism Not serious Light None None
85  Vaginal candidiasis Not serious Light None None
85  Vaginal candidiasis Not serious Light None None
85  Dermatitis Not serious Intermediate None None
85  Urinary tract infection Not serious Intermediate None None
85  Urinary tract infection Not serious Intermediate None None
94  Arthralgia Not serious Intermediate None None
112  Lung cancer Serious Severe Discontinuation of therapy None
123  Headache Not serious Light None None
123  Backache Not serious Light None None
123  Nausea Not serious Light None None
123  Gastro-esophageal reflux Not serious Light None None
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.4. Secondary objectives
The duration of the IE in the two groups was different (10.14
ays in the placebo and 5.83 in the Lantigen B group), but a statisti-
al significance was not achieved (F = 2.724, p = 0.102). The intervals
etween IE were evaluated at the end of the first and second treat-
ent cycle. In the first interval, the differences in the number of
vents (eight in the placebo and five in the treated group) as well
s the mean intervals (in days) were not significant. However, the
umulative hazard of suffering from an IE was 15% for the placebo
nd 9% for the Lantigen B group. Similar results, even if not sta-
istically significant, were observed for the second interval (six EI
or the placebo and two for the Lantigen B group). The relevant
umulative hazards of developing an IE in the second interval were
.11 and 0.035 for placebo and Lantigen B groups. The concomitant
rug use in the treated and in the control groups was also eval-
ated by a logistic regression analysis. For this, three families of
rugs the use of antibiotics and NSAIDs was evaluated in the whole
opulation, while anti-allergic drugs, which included bronchodila-
ors, local corticosteroids and anti-histamine were evaluated in
he subset of allergic patients. No significant differences were
bserved between the treated and control groups, even if a clear
rend was evident: indeed, the treated patients were always treated
ess. Despite the logistic regression analysis demonstrated that
he differences were not significant (p = 0.421, p = 0.134, p = 0.283,
 = 0.519 and p = 0.667 for antibiotics, NSAID, anti-histamine, local
orticosteroids and bronchodilators, respectively), the same statis-
ics showed that probability (Exp(B), also called the odds-ratio) of
sing antibiotics was reduced by 52.1% (being Exp(B) = 0.479) in
he treated patients, of NSAID by 30.2% (Exp(B) = 0.698), of anti-
llergic drugs by 56.2% (Exp(B) = 0.438), of corticosteroids by 41.2%
Exp(B) = 0.588) and of bronchodilators by 25.7% (Exp(B) = 0.734) in
he treated groups. Thus, not only the logistic regression showed
hat for all the drugs the trend was toward a reduction, but fur-
her confirmed the significance of the reduction of the number of IE
p = 0.021 and p = 0.044, for the whole group and the subset of aller-
ic patients). Finally, in both groups, the mean days of absence from
ork were very low (0.79 for placebo and 0.74 days for Lantigen B,
 = 0.925)..5. Adverse reactions (ARs)
With regard to the AR, 21 were recorded for Lantigen B and 23 for
lacebo. The ARs are described in detail in Tables 3a and 3b. Briefly,iate None None
iate None None
the AR of the Lantigen B group occurred in 10 different patients,
while to 17 different patients in the placebo group. Some AR could
be related to the administration of Lantigen B and the placebo,
such as a dry and burning mouth (two episodes in one patient
of the group), stomatitis, odinophagia, and oropharynx burning
(five episodes in the placebo group). The last three AR required
the suspension of the therapy. Other AR included hypothyroidism,
distortion of the left ankle, arthralgia, lung cancer, headache, uri-
nary tract infection, vaginal candidiasis, viral gastroenteritis, oral
herpes, hypertension, nausea and gastro-enteric reflux and were
not related to the treatment. Only lung cancer required the sus-
pension of the drug. The ARs were also classified according to the
severity and the need for therapy interruption (TI). In the placebo
group, the 23 ARs were divided into 11 slight (1 requiring TI), 10
intermediate (requiring TI) and 2 severe, both interrupted. In the
Lantigen B group were 12, 7 and 1 (requiring TI), respectively.
3.6. Epidemiological surveys of the study period
During the study period (namely, September 2012–June 2013),
the circulation of respiratory viruses (both in qualitative and quan-
titative terms) was largely superimposable on that of the previous
year, used as the reference interval for the calculation of the num-
ber of IE for patient recruitment. Fig. 3 shows the results of this
survey: the RSV and influenza viruses were clearly present in the
December–April interval of the two  different periods, while other
viruses, such as adenoviruses and rhinoviruses were detected in
the remaining period.
4. Discussion
In this report, the efficacy of a chemical bacterial lysate, Lanti-
gen B, in the reduction of the number of IE in patients with RRTI has
been clearly demonstrated using a rigorous scientific and clinical
approach. Indeed, this phase IV study was conducted at 12 different
centers, using a double blind, placebo controlled study protocol.
The authors are aware that few studies on the effects of bacterial
lysates have been conducted in the past, using controlled clinical
trials in Good Clinical Practice (GPC) trained hospitals. For this
study, the foreseen number of patients to be recruited was  190 and
30 were expected to be lost during the study. However, the clinical
centers, even though strongly committed, were able to recruit 160
patients. Of these, more than 25% were lost and only 117 patients
could be evaluated at the end of the study. The loss of one-fourth of
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Table  3b
Adverse reaction in the placebo group.
Patient Adverse reaction Seriousness Intensity Action Relationships with the drug
4 Dry and burning mouth Not serious Light None None
5  Dry and burning mouth Not serious Light None None
25  Candidiasis Not serious Intermediate None None
25  Surgery (lipoma removal) Not serious Intermediate None None
26  Hypothyroidism Not serious Intermediate None None
26  Pre-menopausal syndrome Not serious Light None None
42  Dental abscess Not serious Intermediate None None
43  Constipation Not serious Light Discontinuation of therapy Unlikely
65  Backache Not serious Light None None
65  Odinophagia Not serious Severe Discontinuation of therapy Possible
81  Dyspepsia Not serious Intermediate None None
81  Viral gastro-enteritis Not serious Intermediate None None
81  Dyspepsia Not serious Light None None
89  Hypertension Not serious Intermediate None None
97  Fip arthroplasty Serious Severe Discontinuation of therapy None
100  Oropharynx burning Not serious Intermediate Discontinuation of therapy Possible
100  Oropharynx burning Not serious Intermediate Discontinuation of therapy Possible
122  Stomatitis Not serious Intermediate Discontinuation of therapy Possible
133  Oral herpes Not serious Light None None
161  Thoracoalgia Not serious Light None None
165  Migraine Not serious Light None None
165  Migraine Not serious Light None None
168  Conjunctivitis Not serious Light None None
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tig. 3. The cumulative frequencies of virus isolation in the reference period (2011–
he  increased frequency of virus infection in the late winter–early spring periods.
he patient cohort is a relevant phenomenon. Despite this reduc-
ion, the post-hoc analysis showed that the number of evaluable
atients was still sufficient to maintain the statistical relevance of
he study and thus the validity of the observed results. Moreover,
he adverse reactions recorded as well as the causes of dropout
ere extremely heterogeneous and all virtually unrelated to the
reatment. A significant reduction in the number of IE was  observed
n the treated group: an average of 0.86 episodes in the 8 month
tudy period was observed in the Lantigen B treated patients, while
n the placebo group the mean was 1.43 episodes. In this context,
t should be noted that, for the population recruited, the average
umber of previous IE was 5.34/year (corresponding to 3.56/8
onths). As stated before, in the period of the study, the mean
umber of IE in the placebo group was 1.43/8 months (females 1.24
E, males 1.80 IE). This difference may  have different explanations.
ifferent weather and epidemic conditions in the two subsequent
ears, differences in winter and spring climates such as a warmer
emperature or a less aggressive flu virus epidemic may  reduce
he number of respiratory tract infections, allowing the placebo) and in the study period (2012–2013) are represented as histograms. It is evident
to mimic  a pharmacologically positive effect. Moreover, a certain
susceptibility to the effects of a placebo (more evident in females
than in males) and a certain tendency to increase the number of
IE in both groups when describing the severity of their conditions
may  have also influenced the study results. With regard to the
different period epidemiology, it should be noted that the survey
of virus infections in the study season, when compared with that
of the previous “cold” season, showed virtually identical results,
with the main viruses (influenza, rhinoviruses, adenoviruses and
RSV) having the same prevalence in the two  period. Therefore, this
finding did not support the hypothesis of different “infectious”
environments causing a different number of respiratory tract
infections in the study population. The reduction in the number
of IE in the placebo group may  have depended on a well-known
bias, the Hawthorne effect. This phenomenon, originally defined
in an industrial setting [23] has been extended to the realm of
medical research [24,25] and suggests that the subjects’ behavior
or the study results may  be altered by the subjects’ awareness
that they are being studied or if they received additional attention.
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reduced number of acute episodes. Pulm Pharmacol Ther 2014;27(February
(1)):109–13.
[13] Price HC, Henley G. Trial of an oral antigen in upper respiratory tract infections92 F. Braido et al. / Immunolo
t should also be noted that recruitment was based on the num-
er of respiratory tract infections in the previous year. Even if
ot generalized, a certain tendency of patients to (involuntary)
ncrease their reported number of infectious episodes might have
ccurred, and this fact should at least in part explain the differences
bserved. However, to overcome these problems, double blind
lacebo controlled studies (like the present one) are mandatory
o measure the differences between the treatment and placebo
n the same period of the year and in the same locations. In this
ontext, the finding that neither the doctors nor the patients really
ecognized the superior activity of the treatment is also intriguing.
f course, the positive effects of the placebo, as discussed above,
ad a certain role. But, more importantly, the differences observed
ere homogenously distributed between the placebo and the
reated groups. This clearly means that the positive effects of
he administration of bacterial lysates could be observed at a
opulation level while they were less evident at individual level.
n addition, this can also explain why the medical community is
ometimes skeptical about the use of these drugs. Indeed, just
sing personal daily experience and feelings, it is difficult to
stablish whether this family of drugs is active.
Some interesting, if inconclusive data can be derived from the
nalysis of the use of the drugs in the two groups. No statistically
ignificant differences were observed between the placebo and
he treated groups for antibiotics, NSAIDs, bronchodilators, anti-
istamine and local steroids. However, a clear trend was observed
n the treated groups; the use of drugs was always reduced in this
roup. With regard to the small group of allergic patients, the first
bservation was that in the population of RRTI patients, patients
ith allergy symptoms represented 40% of the total. It was evident
hat the treatment with Lantigen B did not significantly alter the
umber of allergic episodes or the number of days with allergy. This
nding was not expected even if the strict correlation between the
llergy symptoms and respiratory infectious diseases could suggest
 potential positive effect [20]. A certain effect was  observed, as a
rend, in the use of anti-allergy drugs: indeed, in allergic patients,
ogistic regression showed that the probability of using drugs spe-
ific for allergy was reduced. Some criticism can be raised on this
tudy: (a) the number of patients recruited, even if statistically cor-
ect, is not very large; (b) during patient’s recruitment and follow
p, functional and laboratory tests were performed only if some IE
r adverse reaction occurred; (c) concomitant diseases, potentially
imicking symptoms of the respiratory tract (such as unknown
rimary immune deficiency – undiagnosed defect however rare in
 study cohort aged between 18 and 65 years) were not specifically
onsidered; (d) the non-perfect synchronism of the recruitment
started in September and closed in December 2012) associated
o the 8-month follow-up, that could at least in part dilute the
ffects of typical infections of the winter–spring period. However,
trengths of the study are several. In particular, (a) the rigorous
andomization homogeneously distributed the abovementioned
iases in the two cohorts; (b) the statistical analyses (ANCOVA and
ogistic regression) not only documented the effects of Lantigen
 on the number of IE, but also identified a clear trend toward
eduction of the use of concomitant therapies in Lantigen B treated
atients; (c) the real life-like enrollment of patients (as stated by
he heterogeneity of adverse reactions not related to the admin-
stration of the drug) is representative of the population that has
aily access to the offices of general practitioners and specialists:
hus, the observed results are reliable.
In conclusion, the administration of Lantigen B, evaluated in
 double blind controlled clinical study, resulted in a significant
eduction in the number of IE in the treated group. In particular,
ot only was the frequency of IE reduced at the population level
ut also at the level of the individual, the number of episodes
as lower in the treated than in the placebo group. The control
[
[ters 162 (2014) 185–193
of respiratory tract infections, at least in the familial or work
environment, results in a reduced spread of the pathogen and in a
reduced use of drugs such as antibiotics, with evident advantages
for the patient and the community. In conclusion, the described
results, together with the significant reduction in concomitant
therapies and the virtual absence of any adverse reactions, indi-
cates that this drug may  be used as an effective first line drug
for the prophylaxis of infectious episodes in patients with RRTI.
The capacity of controlling respiratory tract infections is a finding
particularly relevant in this period, when not only a global increase
of respiratory infections is recorded [24], but also new antibiotics
will not be available on the market for the next years [25].
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